We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.86 | 0.94% | 91.88 | 91.60 | 92.00 | 91.95 | 90.62 | 91.04 | 1,069,033 | 16:40:00 |
From May 2019 to May 2024
By Colin Kellaher
Sanofi SA on Wednesday said it plans to invest more than 600 million euros (US$703 million) to build a new manufacturing plant in Canada aimed at increasing production of its Fluzone flu vaccine.
The Paris pharmaceutical giant said the new plant, which it will build at its existing site in Toronto, will provide more antigen and filling capacity for the high-dose influenza vaccine.
Sanofi said the plant, which it expects to be operational in 2026, will help increase availability of Fluzone in Canada, the U.S. and Europe. The company currently produces the vaccine exclusively at its plant in Swiftwater, Pa.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 31, 2021 10:35 ET (14:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
